Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Coronaviruses
  4. Fast Track Articles
  5. Fast Track Article
image of Exploring the Efficacy of Convalescent Plasma Therapy in COVID-19 Patients: A Clinical Trial Study

Abstract

Background

In December 2019, a group of patients in Wuhan, Hubei province, China, presented with severe illness and pneumonia of unknown origin. Subsequently, a novel coronavirus was identified as the cause and named “2019 novel coronavirus” (2019-nCoV), later defined as “SARS-CoV-2” (Severe Acute Respiratory Syndrome Coronavirus-2), leading to the development of the disease known as COVID-19. This study aimed to evaluate the effectiveness and safety of convalescent plasma as a potential therapy for patients with COVID-19.

Methods

Patients diagnosed with COVID-19 based on real-time polymerase chain reaction (PCR) or CT-Scan symptoms were randomly assigned to either the treatment group (n = 29, received convalescent plasma) or the control group (n = 29). Clinical manifestations and pulmonary involvement were monitored three times during the study. At the end of the intervention, patients were evaluated for clinical symptoms, laboratory test results, and length of hospital stay.

Results

Among the 58 patients who completed the study, there were no significant differences in baseline characteristics between the treatment and control groups upon admission to the hospital. However, the length of hospital stay was significantly shorter (9.54 days) in the convalescent plasma group compared to the control group (12.88 days).

Conclusion

The findings from this study indicate that the use of convalescent plasma therapy, in addition to standard treatment, did not result in reduced mortality or improved clinical outcomes at day 7 when compared to a placebo or control group.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975307584240927114217
2024-10-09
2024-11-26

  • From This Site

    /content/journals/covid/10.2174/0126667975307584240927114217
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Lu R. Zhao X. Li J. Genomic characterisation and epi-demiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020 395 10224 565 574 10.1016/S0140‑6736(20)30251‑8 32007145
    [Google Scholar]
  2. Cossarizza A. De Biasi S. Guaraldi G. Girardis M. Mussini C. SARS‐CoV‐2, the virus that causes COVID‐19: Cytometry and the new challenge for global health. Cytometry A 2020 97 4 340 343 10.1002/cyto.a.24002 32187834
    [Google Scholar]
  3. Huang C. Wang Y. Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 395 10223 497 506 10.1016/S0140‑6736(20)30183‑5 31986264
    [Google Scholar]
  4. Abolghasemi H. Eshghi P. Cheraghali A.M. Clinical effi-cacy of convalescent plasma for treatment of COVID-19 in-fections: Results of a multicenter clinical study. Transfus. Apheresis Sci. 2020 59 5 102875 10.1016/j.transci.2020.102875 32694043
    [Google Scholar]
  5. Abdi M. Coronavirus disease 2019 (COVID-19) outbreak in Iran: Actions and problems. Infect. Control Hosp. Epidemiol. 2020 41 6 754 755 10.1017/ice.2020.86 32192541
    [Google Scholar]
  6. Lasocka J. Bielawski A. Lachert E. Passive immunization in the combat against infectious diseases (COVID-19 included). J Transfus Med 2021 14 2 50 57 10.5603/JTM.2021.0004
    [Google Scholar]
  7. Young M.K. Cripps A.W. Passive immunization for the public health control of communicable diseases: Current status in four high-income countries and where to next. Hum. Vaccin. Immunother. 2013 9 9 1885 1893 10.4161/hv.25311 23783220
    [Google Scholar]
  8. Zeng H. Wang D. Nie J. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: A multi-center case series. Signal Transduct. Target. Ther. 2020 5 1 219 10.1038/s41392‑020‑00329‑x 33024082
    [Google Scholar]
  9. Chen L. Xiong J. Bao L. Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 2020 20 4 398 400 10.1016/S1473‑3099(20)30141‑9 32113510
    [Google Scholar]
  10. Cheng Y. Wong R. Soo Y.O.Y. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 2005 24 1 44 46 10.1007/s10096‑004‑1271‑9 15616839
    [Google Scholar]
  11. Pan F. Ye T. Sun P. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology 2020 295 3 715 721 10.1148/radiol.2020200370 32053470
    [Google Scholar]
  12. Soo Y.O.Y. Cheng Y. Wong R. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin. Microbiol. Infect. 2004 10 7 676 678 10.1111/j.1469‑0691.2004.00956.x 15214887
    [Google Scholar]
  13. Luke T.C. Kilbane E.M. Jackson J.L. Hoffman S.L. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann. Intern. Med. 2006 145 8 599 609 10.7326/0003‑4819‑145‑8‑200610170‑00139 16940336
    [Google Scholar]
  14. Arabi Y.M. Hajeer A.H. Luke T. Feasibility of using con-valescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg. Infect. Dis. 2016 22 9 1554 1561 10.3201/eid2209.151164 27532807
    [Google Scholar]
  15. Duan K. Liu B. Li C. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. USA 2020 117 17 9490 9496 10.1073/pnas.2004168117 32253318
    [Google Scholar]
  16. Mair-Jenkins J. Saavedra-Campos M. Baillie J.K. The effectiveness of convalescent plasma and hyperimmune im-munoglobulin for the treatment of severe acute respiratory in-fections of viral etiology: A systematic review and explorato-ry meta-analysis. J. Infect. Dis. 2015 211 1 80 90 10.1093/infdis/jiu396 25030060
    [Google Scholar]
  17. van Griensven J. Edwards T. de Lamballerie X. Evalua-tion of convalescent plasma for Ebola virus disease in Guin-ea. N. Engl. J. Med. 2016 374 1 33 42 10.1056/NEJMoa1511812 26735992
    [Google Scholar]
  18. Simonovich V.A. Burgos Pratx L.D. Scibona P. A ran-domized trial of convalescent plasma in Covid-19 severe pneumonia. N. Engl. J. Med. 2021 384 7 619 629 10.1056/NEJMoa2031304 33232588
    [Google Scholar]
  19. Agarwal A. Convalescent plasma in the management of mod-erate COVID-19 in adults in India: open label phase II multi-centre randomised controlled trial (PLACID Trial). BMJ 2020 ••• 371
    [Google Scholar]
  20. Liu Z. Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA 2020 324 5 518 519 10.1001/jama.2020.12607 32749486
    [Google Scholar]
  21. Laing A.G. Lorenc A. del Molino del Barrio I. A dynam-ic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 2020 26 10 1623 1635 10.1038/s41591‑020‑1038‑6 32807934
    [Google Scholar]
  22. Bastard P. Rosen L.B. Zhang Q. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020 370 6515 eabd4585 10.1126/science.abd4585 32972996
    [Google Scholar]
/content/journals/covid/10.2174/0126667975307584240927114217
Loading
Exploring the Efficacy of Convalescent Plasma Therapy in COVID-19 Patients: A Clinical Trial Study
Bentham Science Publishers ; https://doi.org/10.2174/0126667975307584240927114217
/content/journals/covid/10.2174/0126667975307584240927114217
/content/journals/covid/10.2174/0126667975307584240927114217
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: convalescent plasma ; Treatment ; COVID-19 ; CT-Scan ; patient ; real-time PCR
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test